clonoSEQ
by Adaptive Biotechnologies
Categories
Laboratory DiagnosticsPredictive Analytics
Description
NGS-based assessment tool for minimal residual disease (MRD) in clinical practice and drug trials.
Summary
clonoSEQ is a next-generation sequencing (NGS) based tool designed by Adaptive Biotechnologies for the highly sensitive assessment of minimal residual disease (MRD) in patients. It is utilized both in clinical practice for monitoring disease progression and remission, and within drug trials to evaluate the efficacy of treatments. This tool leverages the power of immune medicine to offer precise and actionable insights into disease management.
Use Cases
- Monitoring MRD levels in patients undergoing cancer treatment to assess response and remission status.
- Evaluating the efficacy of new oncology drugs in clinical trials through precise MRD measurement.
Platforms
Web
Regulatory Status
not a medical deviceAPI Available
NoAdded to Directory
6/21/2025Target Customer
Clinic